{"id":"W4405998503","doi":"10.1016/s2213-2600(24)00411-9","title":"Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","year":2025,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Manchester Clinical Research Facility; National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; KU Leuven; Fonds Wetenschappelijk Onderzoek; Department of Health and Social Care; National Institute for Health and Care Research; Insmed; Manchester Biomedical Research Centre; Vlaamse regering; Vertex Pharmaceuticals; Cystic Fibrosis Trust; Mylan; Deutsche Forschungsgemeinschaft; Arrowhead Pharmaceuticals; Koning Boudewijnstichting; Cystic Fibrosis Foundation Therapeutics; AstraZeneca; European Respiratory Society; American Thoracic Society","keywords":"Ivacaftor; Medicine; Cystic fibrosis; Evening; Spirometry; Cystic fibrosis transmembrane conductance regulator; Internal medicine; Physical therapy; Asthma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002963227,0.001079813,0.00229823,0.0003847958,0.0003669612,0.0009176746,0.0005995847,0.002064105,0.005296134],"category_scores_gemma":[0.003289268,0.0004215245,0.00375584,0.0003123358,0.0007978228,0.001135686,0.0004641825,0.002263213,0.0005637307],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006170139,"about_ca_system_score_gemma":0.001005132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000745231,"about_ca_topic_score_gemma":0.00225953,"domain_scores_codex":[0.9983432,0.0008894096,0.0002069485,0.0002546595,0.0001097024,0.0001959555],"domain_scores_gemma":[0.9978951,0.0006743243,0.0007092031,0.00009891685,0.0001482532,0.0004741811],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9656266,0.003033086,0.001257462,0.001606282,0.002261075,0.00003875022,0.00008958529,0.0002384621,0.003617722,0.0001402448,0.0006595238,0.0214312],"study_design_scores_gemma":[0.8740155,0.1169382,0.005069929,0.0001716818,0.00181078,0.00007719479,0.00003868383,0.0001897007,0.0004682992,0.0002024637,0.0009923149,0.00002530312],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9655362,0.02612723,0.0006299815,0.0007922534,0.0006319215,0.003072653,0.001175601,0.00006998326,0.001964242],"genre_scores_gemma":[0.9832217,0.006830617,0.00180069,0.001258814,0.0005071533,0.003473314,0.001035471,0.0000202335,0.001852138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005296134,"threshold_uncertainty_score":0.01771736,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08325670678336557,"score_gpt":0.407447650453088,"score_spread":0.3241909436697225,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}